Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine. These results show that once-daily treatment with single inhaler, high- and medium-dose Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) demonstrated non-inferiority to a free combination of twice-daily, high-dose salmeterol xinafoate/fluticasone propionate (Sal/Flu) plus once-daily tiotropium (Tio), delivered in two different devices, in improving quality of life in people with uncontrolled asthma. Among secondary analyses, improvements in lung function, asthma control, health status, and reductions in moderate exacerbations were observed with high-dose once-daily IND/GLY/MF compared to high-dose Sal/Flu plus Tio.
source https://www.pharmatutor.org/pharma-news/2020/novartis-phase-iiib-argon-study-meets-primary-endpoint-in-a-comparison-of-enerzair-breezhaler-versus-a-free-combination-of-two-existing-inhaled-treatments-in-uncontrolled-asthma
No comments:
Post a Comment